Levofloxacin reasonable alternative to TMP-SMX for S maltophilia infections: Study
USA: A recent study, based on observational evidence showed that levofloxacin is a reasonable alternative to trimethoprim-sulfamethoxazole (TMP-SMX) for treating bloodstream and lower respiratory tract infections caused by S maltophilia. The study was published in the journal Open Forum Infectious Diseases on 17 January 2022.
Based on observational data from small studies, TMP-SMX is considered first-line therapy for Stenotrophomonas maltophilia infections. Levofloxacin has emerged as a popular alternative owing to tolerability concerns related to TMP-SMX. There is a lack of data comparing levofloxacin to TMP-SMX as targeted therapy.
To fill this knowledge gap, Sameer S Kadri, Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA, and colleagues used a large electronic health record database to conduct a retrospective comparative effectiveness study of levofloxacin vs TMP-SMX for BSIs and LRTIs due to S maltophilia using a large electronic health record database.
For this purpose, the researchers identified adult inpatient encounters from January 2005 through December 2017 with the growth of S maltophilia in blood and/or lower respiratory cultures in the Cerner Health facts database. The patients who were included received targeted therapy with either levofloxacin or TMP-SMX. Overlap weighting was used followed by downstream weighted regression.
Adjusted odds ratio (aOR) for in-hospital mortality or discharge to hospice was the primary outcome. The secondary outcome was the number of days from index S maltophilia culture to hospital discharge.
Based on the findings, the researchers found the following:
- Among 1581 patients with S maltophilia infections, levofloxacin (n = 823) displayed statistically similar mortality risk (aOR, 0.76 compared to TMP-SMX (n = 758).
- Levofloxacin (vs TMP-SMX) use was associated with a lower aOR of death in patients with lower respiratory tract infection (n = 1452) (aOR, 0.73) and if initiated empirically (n = 89) (aOR, 0.16).
- The levofloxacin cohort had fewer hospital days between index culture collection and discharge (weighted median, 7 vs 9 days).
"Based on observational evidence we found that levofloxacin is a reasonable alternative to TMP-SMX for the treatment of bloodstream and lower respiratory tract infections caused by S maltophilia," wrote the authors.
"Consider levofloxacin in patients with diagnosed S maltophilia infections sensitive to TMP-SMX tolerability limitations, especially those who are neutropenic, critically ill," they concluded.
Reference:
Sadia H Sarzynski, Sarah Warner, Junfeng Sun, Roland Matsouaka, John P Dekker, Ahmed Babiker, Willy Li, Yi Ling Lai, Robert L Danner, Vance G Fowler, Jr, Sameer S Kadri, for the National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative, Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals, Open Forum Infectious Diseases, Volume 9, Issue 2, February 2022, ofab644, https://doi.org/10.1093/ofid/ofab644
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.